Table 5. Urinary chondroitin sulfate (CS) and hyaluronic acid (HA) excretion and incidence of urolithiasis in urolithic hyperoxaluric rats.
| Group | Urine CS (mg/g creatinine) | Urine HA (mg/g creatinine) | Stone formation (cases/total) | ||||
|---|---|---|---|---|---|---|---|
| Day 0 | Day 8 | Day 15 | Day 0 | Day 8 | Day 15 | ||
| Control | 1.18+0.43 | 1.11+0.30 | 1.35+0.36 | 0.13+0.11 | 0.12+0.09 | 0.11+0.09 | 0/9 |
| Urolithiasis | 1.39+0.40 | 1.39+0.39 | 1.81+0.64 | 0.13+0.10 | 0.15+0.12 | 0.19+0.12 | 8/8 |
| CS supplement | 1.37+0.48 | 3.37+1.33* | 4.68+0.68* | 0.18+0.09 | 0.15+0.07 | 0.18+0.10 | 3/9# |
| HA supplement | 1.28+0.37 | 1.77+0.63 | 1.88+0.59 | 0.18+0.10 | 0.84+0.29* | 0.87+0.18* | 9/9 |
| CS&HA supplement | 1.36+0.47 | 3.12+1.39* | 4.39+0.57* | 0.17+0.06 | 0.74+0.14* | 1.01+0.38* | 5/8# |
*p < 0.05 compared with day 0
#p < 0.05 compared with Control